نتایج جستجو برای: blocker therapy
تعداد نتایج: 668728 فیلتر نتایج به سال:
BACKGROUND Histoplasmosis may complicate tumor necrosis factor (TNF)-α blocker therapy. Published case series provide limited guidance on disease management. We sought to determine the need for long-term antifungal therapy and the safety of resuming TNF-α blocker therapy after successful treatment of histoplasmosis. METHODS We conducted a multicenter retrospective review of 98 patients diagno...
Perioperative beta-blocker therapy has been considered a mainstay of perioperative cardioprotection in patients with or at risk of coronary artery diseases. However, current recommendations for perioperative beta blockade are based mainly on the findings of trials with inadequate methodology and data analysis. The recently published results of the first adequately powered large controlled rando...
Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patient...
BACKGROUND AND AIM Recently, β-blockers have been suggested as a potential maintenance treatment option for asthma. The aim of this review is to provide an overview of the current knowledge of the potential benefits and risks of β-blocker therapy for asthma. METHOD Systematic literature review. RESULTS No significant increase in the number of patients requiring rescue oral corticosteroid fo...
Bevacizumab-induced kidney side effects are common, mainly presented by blood hypertension (BH) and proteinuria (Pr), that generally resolve on drug withdrawal angiotensin-system blocker therapy. There is no standard threatment approach in cases of severe bevacizumab-induced injury associated with thrombotic microangiopathy (TMA). Eculizumab has been shown to be effective some these patients.
BACKGROUND AND OBJECTIVE Recent clinical trials indicate that combining an alpha blocker for rapid symptom improvement and a 5-alpha reductase inhibitor (5-ARI) to reduce the risk of clinical progression of benign prostatic hyperplasia (BPH) may be an optimal approach to management; however, few studies have evaluated the effect of combination therapy on clinical progression in a real-world set...
eta-blockers have been found not to be effective for rimary prevention of cardiovascular disease in patients with rimary hypertension. The problem was first recognized by esserli et al. (1) in 1998. They pointed out the signifiantly lesser benefit of beta-blocker therapy in 2 trials versus iuretic-based therapy in 7 separate trials. Their presentaion could not have been clearer: “Diuretic thera...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید